Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013491
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc (VER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Partnerships 12
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Licensing Agreements 19
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Equity Offering 24
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc – Key Competitors 27
Vernalis Plc – Key Employees 28
Vernalis Plc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017 31
Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results 33
Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016 34
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016 36
Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015 38
Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015 43
Corporate Communications 44
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics 44
Government and Public Interest 45
Dec 01, 2016: Vernalis: AGM Statement 45
Product News 46
12/21/2016: FDA accepts CCP-08 NDA for full review 46
09/06/2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review 47
04/05/2017: Drug makes head-and-neck cancer more sensitive to radiotherapy 48
Product Approvals 49
Aug 07, 2017: FDA Issues a Complete Response Letter on CCP-08 NDA 49
Apr 21, 2017: FDA Issues a Complete Response Letter on CCP-07 NDA 50
Clinical Trials 51
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 51
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 52
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc, Key Competitors 27
Vernalis Plc, Key Employees 28
Vernalis Plc, Subsidiaries 29

★海外企業調査レポート[Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wintac Ltd (524758):企業の財務・戦略的SWOT分析
    Summary Wintac Ltd (Wintac), formerly Recon Ltd is a manufacturer and marketer of sterile products. The company offers opthalmic products such as anti-glaucoma, anti-cholinergic, artificial tear, NSAID, steroids and combination, anti-infective, decongestant, anti allergic eye drops and nasal drop, a …
  • Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析
    Summary Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a medical biotechnology company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company designs and develops immunomodulator microparticle technology. Innat …
  • Innovation Pharmaceuticals Inc (IPIX)-医療機器分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company pipeline products include kevetrin for the …
  • Mexco Energy Corp (MXC):石油・ガス:M&Aディール及び事業提携情報
    Summary Mexco Energy Corp (Mexco Energy) is an oil and gas company that offers exploration, acquisition, production, and development of crude oil, natural gas, condensate liquids, and natural gas liquids. The company acquires producing and non-producing oil and gas leases from landowners and leaseho …
  • Genocea Biosciences Inc (GNCA):企業の財務・戦略的SWOT分析
    Summary Genocea Biosciences Inc (Genocea), formerly Genocea Inc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas tec …
  • Musgrave Group Plc:企業の戦略・SWOT・財務情報
    Musgrave Group Plc - Strategy, SWOT and Corporate Finance Report Summary Musgrave Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析
    Summary Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company's pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treatin …
  • Canadian Tire Corp Ltd (CTC.A):企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Aben Resources Ltd (ABN):企業の財務・戦略的SWOT分析
    Summary Aben Resources Ltd (Aben Resources) is a mining and mineral exploration and development company. The company offers o acquisition, exploration, operations, mining, management production, and development of lithium, uranium, gold, lead, silver, zinc, copper, and mineral resource deposit prope …
  • Societe Nationale d’Operations Petrolieres de la Cote d’Ivoire:石油・ガス:M&Aディール及び事業提携情報
    Summary Societe Nationale d'Operations Petrolieres de la Cote d'Ivoire (Petroci) is an oil and gas company that explores, produces and trades petroleum products and by-products. The company offers butane gas, natural gas and LPG. It provides oil trading and logistics services. Petroci conducts geolo …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • Rocky Brands, Inc. (RCKY):企業の財務・戦略的SWOT分析
    Rocky Brands, Inc. (RCKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Fidia farmaceutici SpA-製薬・医療分野:企業M&A・提携分析
    Summary Fidia farmaceutici SpA (Fidia), a subsidiary of P&R S.p.A., is a healthcare products provider that specializes in research, development and manufacturing of hyaluronic acid-based products. The company develops and commercializes products for specific therapeutic areas which includes joint he …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Space Exploration Technologies Corp:企業の戦略・SWOT・財務情報
    Space Exploration Technologies Corp - Strategy, SWOT and Corporate Finance Report Summary Space Exploration Technologies Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • CenterPoint Energy Inc (CNP):電力:M&Aディール及び事業提携情報
    Summary CenterPoint Energy Inc (CenterPoint) is an energy utility company that carries out electric transmission and distribution, and natural gas distribution. It is also involved in natural gas sales and service, pipeline services and other field services. The company sells regulated intrastate na …
  • Marsh & McLennan Companies, Inc.:企業の戦略・SWOT・財務情報
    Marsh & McLennan Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Marsh & McLennan Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • L Brands Inc:戦略・SWOT・企業財務分析
    L Brands Inc - Strategy, SWOT and Corporate Finance Report Summary L Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Kinder Morgan, Inc.:企業の戦略・SWOT・財務分析
    Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Harbor MedTech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Harbor MedTech Inc (Harbor MedTech) is a commercial-stage regenerative medicine company that offers tissue regeneration solutions. The company offers Architect, an extracellular collagen matrix used in managing partial and full thickness wounds. Its collagen wound matrix systems are used in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆